Avelumab combination designated a breakthrough therapy by the FDA

The immunotherapy drug avelumab (Bavencio) has been designated a breakthrough therapy by the US Food and Drug Administration (FDA) for the second time, this time for use in combination with axitinib (Inlyta) for people with advanced renal cell carcinoma (RCC) who have received no previous treatment. The breakthrough therapy designation speeds up the development and […]

read more
Showing 11 to 11 of 11 results
  TOP